STRIDES ARCOLAB LTD
RESULTS FOR Q/E DEC,2013
STRIDES ARCOLAB Ltd has announced good results for the
fourth quarter ended Dec,2013. It has however extended the results period by
another quarter upto March 2014.
HIGH LIGHTS
GLOBAL
PHARMA
·
Three Notch Upgrade to A+ By India Ratings (A
Fitch group Co.)
·
Revenue Guidance of Rs.1000 cr and EBITDA
Guidance of Rs.200 Cr. Met despite delays in anticipated product approvals from
USFDA.
·
Consolidated Pharma revenues for YTD Dec,13 at
Rs.1035 Cr with an EBOTDA of Rs.201 Cr – impacted by an exchange loss of Rs.22
Cr (EBITDA Margin of 19%)
·
Adjusted for Exchange loss, YTD Dec,13 EBITDA
ar. Rs.223 cr, EBITDA Margin of 22%
·
Q4 FY 13 consolidated Pharma revenues at Rs.326
Cr with an EBITDA of Rs.60 Cr.
·
Q4 13 consolidated pharma EBITDA grew by 100+%
(Rs.60 Cr. In Q4 2013 against Rs.28 cr in Q4 2012)
·
Strong offtake in institutional business with
the launch of recently approved Anti-Malarial product
·
47 filings as on date with US FDA with 18
pending approvals
Biotech
·
Stelis Biopharma entered into a long term
agreement with Germany’s Pieris AG for worldwide development and
commercialization of a protein Molecule, primarily focused on Ophthalmology .
·
This has been a defining quarter for all of us
at strides as we delivered significant value to all stakeholders post the
successful completion of the Agila transaction. The continuing Global Pharma
Business has delivered the 12 month Guidance despite delays in key product
approvals from US FDA. We expect to continue the momentum in the coming
quarters – said Arun Kumar, Vice Chairman and Group CEO, Strides Arcolab Ltd.
·
Item (Crs) Q4’13 Q4’12 GROWTH%
·
Revenues 276 229 20%
·
EBITDA 50 61 -17%
·
PBT 4643 78 100+%
·
PAT 3525 74 100+%
·
EPS Rs.597 Rs.12.58 100+%
·
The Financial Year changed from Jan-Dec to
April-March. Current FY will end as 15 months ended march,2014
·
Strides is HQed in Bangalore ; has 5
Manufacturing facilities; has presence in more than 75 countries in developed
and emerging markets.
RESULTS TABLE (Stand Alone)
|
Strides
Arcolab
|
31-12-13
|
30-09-13
|
Dif%
QoQ
|
31-12-12
|
Dif%
YoY
|
|
Net
Sales
|
24024.33
|
19918.13
|
20.62
|
15209.06
|
57.96
|
|
Total
Expenditure
|
23543.61
|
18306.56
|
28.61
|
17450.87
|
34.91
|
|
Total
Income
|
25337.58
|
20894.2
|
21.27
|
17744.42
|
42.79
|
|
Profit before tax
|
464273.81
|
541.5
|
85638.47
|
7783.07
|
5865.18
|
|
Tax
Expenses
|
111749.68
|
320
|
34821.78
|
390
|
28553.76
|
|
Net
Profit
|
352524.13
|
221.5
|
159053.11
|
7393.07
|
4668.31
|
|
Face
Value(Rs )
|
10
|
10
|
0
|
10
|
0
|
|
Basic
EPS
|
597
|
0.38
|
157005.26
|
12.58
|
4645.63
|
|
Diluted
EPS
|
595.12
|
0.37
|
160743.24
|
12.46
|
4676.24
|
|
Public
holding (%)
|
72.83
|
72.64
|
0.26
|
72.49
|
0.47
|
* *
* E N D *
* *
No comments:
Post a Comment